Morgan Stanley’s NeoGenomics NEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$27.7M Sell
1,898,128
-264,655
-12% -$2.55M ﹤0.01% 2792
2026
Q1
$16M Buy
2,162,783
+36,734
+2% +$387K ﹤0.01% 3162
2025
Q4
$25M Sell
2,126,049
-531,967
-20% -$5.74M ﹤0.01% 2722
2025
Q3
$20.5M Buy
2,658,016
+169,529
+7% +$1.19M ﹤0.01% 2873
2025
Q2
$18.2M Buy
2,488,487
+942,228
+61% +$7.6M ﹤0.01% 2905
2025
Q1
$14.7M Sell
1,546,259
-248,019
-14% -$3.1M ﹤0.01% 2997
2024
Q4
$29.6M Sell
1,794,278
-136,771
-7% -$2.12M ﹤0.01% 2351
2024
Q3
$28.5M Buy
1,931,049
+289,688
+18% +$4.53M ﹤0.01% 2433
2024
Q2
$22.8M Sell
1,641,361
-171,847
-9% -$2.44M ﹤0.01% 2508
2024
Q1
$28.5M Sell
1,813,208
-151,358
-8% -$2.34M ﹤0.01% 2304
2023
Q4
$31.8M Sell
1,964,566
-30,882
-2% -$505K ﹤0.01% 2202
2023
Q3
$24.5M Sell
1,995,448
-148,867
-7% -$2.21M ﹤0.01% 2239
2023
Q2
$34.5M Buy
2,144,315
+20,095
+0.9% +$331K ﹤0.01% 1929
2023
Q1
$37M Buy
2,124,220
+303,463
+17% +$4.32M ﹤0.01% 1828
2022
Q4
$16.8M Buy
1,820,757
+276,117
+18% +$2.57M ﹤0.01% 2517
2022
Q3
$13.3M Buy
1,544,640
+227,032
+17% +$2.25M ﹤0.01% 2652
2022
Q2
$10.7M Buy
1,317,608
+511,137
+63% +$4.88M ﹤0.01% 3000
2022
Q1
$9.8M Sell
806,471
-55,559
-6% -$1.17M ﹤0.01% 2926
2021
Q4
$29.4M Sell
862,030
-89,267
-9% -$3.5M ﹤0.01% 1759
2021
Q3
$45.9M Buy
951,297
+68,505
+8% +$3.17M 0.01% 1356
2021
Q2
$39.9M Buy
882,792
+36,349
+4% +$1.61M 0.01% 1490
2021
Q1
$40.8M Buy
846,443
+269,610
+47% +$14M 0.01% 1323
2020
Q4
$31.1M Sell
576,833
-122,155
-17% -$5.52M ﹤0.01% 1443
2020
Q3
$25.8M Buy
698,988
+249,470
+55% +$9.27M 0.01% 1303
2020
Q2
$13.9M Sell
449,518
-63,792
-12% -$1.77M ﹤0.01% 1684
2020
Q1
$14.2M Sell
513,310
-100,070
-16% -$3M ﹤0.01% 1525
2019
Q4
$17.9M Sell
613,380
-35,863
-6% -$854K ﹤0.01% 1759
2019
Q3
$12.4M Buy
649,243
+49,737
+8% +$1.17M ﹤0.01% 1906
2019
Q2
$13.2M Sell
599,506
-26,755
-4% -$587K ﹤0.01% 1869
2019
Q1
$12.8M Sell
626,261
-19,370
-3% -$337K ﹤0.01% 1795
2018
Q4
$8.14M Sell
645,631
-411,286
-39% -$6.13M ﹤0.01% 2345
2018
Q3
$16.2M Buy
1,056,917
+927,403
+716% +$12.8M ﹤0.01% 1887
2018
Q2
$1.7M Sell
129,514
-132,872
-51% -$1.46M ﹤0.01% 4229
2018
Q1
$2.14M Buy
262,386
+119,665
+84% +$969K ﹤0.01% 3946
2017
Q4
$1.26M Sell
142,721
-335,146
-70% -$3.09M ﹤0.01% 4386
2017
Q3
$5.32M Buy
477,867
+45,562
+11% +$443K ﹤0.01% 2901
2017
Q2
$3.87M Sell
432,305
-13,509
-3% -$107K ﹤0.01% 3147
2017
Q1
$3.52M Sell
445,814
-72,161
-14% -$588K ﹤0.01% 3249
2016
Q4
$4.44M Buy
517,975
+153,785
+42% +$1.32M ﹤0.01% 3121
2016
Q3
$2.99M Sell
364,190
-47,075
-11% -$395K ﹤0.01% 3163
2016
Q2
$3.31M Buy
411,265
+50,448
+14% +$404K ﹤0.01% 2985
2016
Q1
$2.43M Buy
360,817
+236,934
+191% +$1.56M ﹤0.01% 3189
2015
Q4
$975K Sell
123,883
-316,219
-72% -$2.32M ﹤0.01% 4062
2015
Q3
$2.52M Buy
440,102
+75,221
+21% +$466K ﹤0.01% 3289
2015
Q2
$1.97M Sell
364,881
-146,894
-29% -$757K ﹤0.01% 3635
2015
Q1
$2.39M Buy
511,775
+213,079
+71% +$926K ﹤0.01% 3435
2014
Q4
$1.25M Sell
298,696
-53,544
-15% -$246K ﹤0.01% 3970
2014
Q3
$1.84M Buy
352,240
+238,134
+209% +$1.22M ﹤0.01% 3516
2014
Q2
$378K Buy
114,106
+20,828
+22% +$69.2K ﹤0.01% 4775
2014
Q1
$324K Sell
93,278
-93,848
-50% -$352K ﹤0.01% 4844
2013
Q4
$677K Buy
187,126
+117,654
+169% +$408K ﹤0.01% 4242
2013
Q3
$209K Buy
69,472
+14,399
+26% +$40.6K ﹤0.01% 4861
2013
Q2
$219K Buy
+55,073
New +$210K ﹤0.01% 4792

Other funds holding NEO

Morgan Stanley's NEO Position: Q2 2026 in Review

Morgan Stanley reduced its NeoGenomics (NEO) stake by 12% in Q2 2026, selling an estimated $2.55M and leaving 1,898,128 shares worth $27.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2792.

Morgan Stanley first reported a position in NEO in Q2 2013 and has held it in 53 quarters since. The position peaked at $45.9M in Q3 2021. 266 funds tracked by Wall St. Rank hold NEO as of Q2 2026.

  • Morgan Stanley held 1,898,128 shares of NeoGenomics worth $27.7M as of Q2 2026.
  • Morgan Stanley sold 264,655 NeoGenomics shares in Q2 2026, an estimated $2.55M.
  • NeoGenomics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #2792 holding.
  • Morgan Stanley first reported a position in NeoGenomics in Q2 2013 and has held it in 53 quarters since.
  • Morgan Stanley's NeoGenomics position peaked at $45.9M in Q3 2021.
  • 266 funds tracked by Wall St. Rank held NeoGenomics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.